Bienville Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $294K | Hold |
58,053
| – | – | 0.06% | 60 |
|
|
2025
Q1 | $307K | Hold |
58,053
| – | – | 0.07% | 57 |
|
|
2024
Q4 | $392K | Hold |
58,053
| – | – | 0.1% | 66 |
|
|
2024
Q3 | $383K | Hold |
58,053
| – | – | 0.1% | 64 |
|
|
2024
Q2 | $435K | Hold |
58,053
| – | – | 0.1% | 61 |
|
|
2024
Q1 | $579K | Hold |
58,053
| – | – | 0.18% | 55 |
|
|
2023
Q4 | $572K | Hold |
58,053
| – | – | 0.16% | 58 |
|
|
2023
Q3 | $444K | Buy |
58,053
+1,177
| +2% | +$9K | 0.12% | 61 |
|
|
2023
Q2 | $425K | Hold |
56,876
| – | – | 0.14% | 58 |
|
|
2023
Q1 | $379K | Hold |
56,876
| – | – | 0.14% | 65 |
|
|
2022
Q4 | $439K | Sell |
56,876
-4,062
| -7% | -$31.3K | 0.13% | 60 |
|
|
2022
Q3 | $648K | Buy |
60,938
+24,375
| +67% | +$259K | 0.25% | 50 |
|
|
2022
Q2 | $298K | Hold |
36,563
| – | – | 0.14% | 96 |
|
|
2022
Q1 | $262K | Hold |
36,563
| – | – | 0.13% | 115 |
|
|
2021
Q4 | $626K | Buy |
+36,563
| New | +$626K | 0.45% | 44 |
|